DGAP-News: Cytos Biotechnology Ltd invites to an Extraordinary Shareholders' Meeting in December 2013
EQS Group-News: Cytos Biotechnology AG / Key word(s): AGM/EGM
Cytos Biotechnology Ltd invites to an Extraordinary Shareholders'
Meeting in December 2013
04.12.2013 / 07:00
---------------------------------------------------------------------
Dr. Yamo Deniz to join Cytos Biotechnology's Board of Directors
Schlieren (Zurich), Switzerland, December 4, 2013 - Cytos Biotechnology Ltd
(SIX:CYTN) ('Cytos' or the 'Company') today announced that Dr. Yamo Deniz
is proposed to join Cytos' Board of Directors. Dr. Deniz played a key role
in the filing and approval of multiple drugs and in-vivo diagnostics agents
in several therapeutic areas of unmet need, including omalizumab
(Xolair(R)) for the treatment of asthma in the US and the EU. His extensive
experience in the clinical development of asthma products further
strengthens Cytos' Board of Directors.
Dr. Christian Itin, Chairman and CEO of Cytos, said: 'With Dr. Yamo Deniz
we are strengthening our Board of Directors with an industry expert in
allergic asthma, the key area of focus for our lead program CYT003. His
experience in developing, obtaining approval for and commercialization of
the first biological in asthma is highly relevant for the development and
positioning of CYT003. Dr. Yamo Deniz will join as an independent
director.'
About Dr. Yamo Deniz
Yamo Deniz, MD, currently serves as Chief Medical Officer, Global Head of
Medical & Pharmacovigilance at GE Healthcare Lifesciences. Prior to joining
GEHC in 2010, Dr. Deniz held numerous senior clinical and leadership
positions of increasing responsibilities in respiratory as well as
inflammation groups at Genentech and Roche, respectively. Dr. Deniz played
a key role in the filing and approval of multiple drugs and in-vivo
diagnostics agents in several therapeutic areas of unmet need, including
omalizumab (Xolair(R)) for the treatment of asthma in the US and the EU. He
also oversaw the lifecycle management plans of marketed products for other
indications. In addition, he led Genentech's Peanut Allergy program. Dr.
Deniz graduated with a BA in Chemistry from the College of the Holy Cross.
After finishing his medical studies at the University of Massachusetts, Dr.
Deniz completed a pediatric residency in New York and a sub-specialty
training in Pediatric Allergy & Immunology at Duke University Medical
Center in North Carolina. Prior to joining Genentech in 2001, Dr. Deniz
worked at the Karolinska Institutet Pediatric Hospital and remains actively
involved in the respiratory, allergy and immunology fields. He currently
also serves as a member of the corporate scientific advisory board of DBV
Technologies.
Extraordinary Shareholders' Meeting on December 30, 2013
In order to elect Dr. Deniz to the Board of Directors, an extraordinary
shareholders' meeting will be held on December 30, 2013. Additional agenda
items at this meeting are an increase of the authorized share capital by
2'715'946 registered shares and an increase of the conditional share
capital for financing purposes by 905'315 registered shares, bringing both
authorized and conditional share capital to 50% of the issued share
capital. In addition, the Board proposes an amendment to the resolution no.
2 of the annual general meeting of shareholders held on June 28, 2013
(Compensation of Loss). The invitation for the shareholders meeting will be
mailed to registered shareholders within the next few days.
The invitation including the agenda is available for downloading at
http://www.cytos.com/uploads/2013/Cytos_invitation_EGM_FINAL_131230.pdf
For further information, please contact:
Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel: +41 44 733 46 46
e-mail: harry.welten@cytos.com
US Investor enquiries
Susan A. Noonan
Tel: +1 (212) 966 3650
e-mail: susan@sanoonan.com
About Cytos Biotechnology Ltd
Cytos is a public biopharmaceutical company focused on the development of
targeted immuno-therapies. The Company's lead product candidate CYT003 is a
novel, first-in-class, immune modulator in Phase 2 clinical development as
a potential new treatment for asthma.
CYT003 has a novel mechanism of action that inhibits the immune response
that causes asthma, and may therefore be beneficial for the control of
asthma. In a successfully completed Phase 2a study, CYT003 was shown to
maintain asthma control and lung function in patients with persistent
allergic asthma, despite withdrawal of standard therapy with inhaled
corticosteroids. CYT003 has been shown to have a good safety and
tolerability profile in more than 450 individuals receiving the active
agent so far.
Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of
Technology (ETH) in Zurich. It is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.
www.cytos.com
Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words 'committed', 'could', 'will', 'plans',
'enable', 'expected', 'proposed', 'intends', 'planned,' or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, including that CYT003
may not demonstrate safety or efficacy in clinical trials, that there may
be delays in development or that CYT003 may not receive marketing approval,
and that the Company relies on outside financing to meet capital
requirements, which may not be available under acceptable terms or at all.
Against the background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
developments.
End of Corporate News
+++++
Additional features:
Document: http://n.equitystory.com/c/fncls.ssp?u=QNMBLNRTVU
Document title: Cytos_Press_E_131204
---------------------------------------------------------------------
04.12.2013 This Corporate News was distributed by EQS Schweiz AG.
www.eqs.com - news archive: http://switzerland.eqs.com/de/News
The issuer is responsible for the contents of the release.
---------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Switzerland
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info@cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Valor: -
Listed: Freiverkehr in Berlin, München, Stuttgart; Frankfurt in
Open Market ; SIX
End of News EQS Group News-Service
---------------------------------------------------------------------
242954 04.12.2013